Eli Lilly and Company (NYSE:LLY) Receives $1,304.86 Average Target Price from Analysts

Shares of Eli Lilly and Company (NYSE:LLY) have been assigned an average recommendation of “Moderate Buy” from the thirty research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $1,305.25.

A number of analysts recently weighed in on LLY shares. Royal Bank Of Canada increased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. HSBC boosted their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Bank of America increased their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a research report on Friday, August 7th. Finally, Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA granted full approval to Inluriyo (imlunestrant) plus Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In the Phase 3 EMBER-3 trial, the combination doubled median progression-free survival versus Inluriyo alone, expanding Lilly’s oncology commercial opportunity. FDA approves Inluriyo and Verzenio
• Positive Sentiment: Guggenheim raised its price target to $1,284, citing continued strength in the tirzepatide franchise and improving Foundayo trends. Berenberg also upgraded Lilly to Buy and lifted its target to $1,400, pointing to strong returns on research investment and obesity-market growth. Guggenheim raises Lilly price target Berenberg upgrades Lilly
• Positive Sentiment: Analysts continue to view Lilly’s GLP-1 portfolio, including Mounjaro and Zepbound, as a major growth engine. The company’s recent revenue growth and pipeline of next-generation obesity treatments underpin the bullish long-term outlook. Bullish outlook for Lilly
• Neutral Sentiment: Investors are awaiting the September 30 mid-stage data readout for the eloraTZP two-drug obesity treatment. Strong efficacy could support Lilly’s premium valuation and create a new franchise, while only incremental benefits could intensify concerns that expectations are already too high. Lilly obesity combination data outlook
• Negative Sentiment: Lilly’s U.S. pricing reportedly fell 9% year over year, with higher sales volume currently offsetting the decline. Investors may become more cautious if pricing pressure begins to outpace volume growth. Lilly pricing pressure analysis
• Negative Sentiment: The stock’s premium valuation, increasing competition in obesity drugs and recent performance concerns remain potential headwinds despite strong fundamentals. Lilly valuation and competition analysis

Eli Lilly and Company Stock Down 0.0%

NYSE:LLY opened at $1,152.62 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 12-month low of $712.05 and a 12-month high of $1,292.65. The stock’s fifty day simple moving average is $1,176.90 and its 200-day simple moving average is $1,077.21. The firm has a market capitalization of $1.09 trillion, a P/E ratio of 38.68, a P/E/G ratio of 1.42 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts expect that Eli Lilly and Company will post 36.54 earnings per share for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by company insiders.

Institutional Trading of Eli Lilly and Company

Large investors have recently bought and sold shares of the business. Norges Bank bought a new stake in Eli Lilly and Company in the 4th quarter valued at $12,976,634,000. Bank of America Corp DE bought a new position in Eli Lilly and Company during the 2nd quarter worth about $13,522,666,000. Jupiter Topco LLC acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $4,667,180,000. Fifth Third Bancorp lifted its holdings in shares of Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Eli Lilly and Company by 353.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock valued at $1,425,859,000 after purchasing an additional 1,208,510 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.